Kenji Chamoto

6.5k total citations · 4 hit papers
85 papers, 4.4k citations indexed

About

Kenji Chamoto is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Kenji Chamoto has authored 85 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Immunology, 41 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Kenji Chamoto's work include Immune Cell Function and Interaction (44 papers), Immunotherapy and Immune Responses (34 papers) and T-cell and B-cell Immunology (23 papers). Kenji Chamoto is often cited by papers focused on Immune Cell Function and Interaction (44 papers), Immunotherapy and Immune Responses (34 papers) and T-cell and B-cell Immunology (23 papers). Kenji Chamoto collaborates with scholars based in Japan, United States and Germany. Kenji Chamoto's co-authors include Tasuku Honjo, Takashi Nishimura, Partha S. Chowdhury, Daiko Wakita, Alok Kumar, Junzo Hamanishi, Yoshiko Iwai, Hidemitsu Kitamura, Takayuki Ohkuri and Tsuguhide Takeshima and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Kenji Chamoto

84 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunotherapies targeting the PD-1 signaling pathway

2017 488 citations Kenji Chamoto, Tasuku Honjo et al. profile →
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

2017 314 citations Kenji Chamoto, Partha S. Chowdhury et al. profile →
PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy

2018 268 citations Partha S. Chowdhury, Kenji Chamoto et al. Cancer Immunology Research profile →
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1

2023 95 citations Kenji Chamoto, Tomonori Yaguchi et al. Nature reviews. Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenji Chamoto Japan	35	2.6k	2.0k	1.0k	516	393	85	4.4k
Shinichiro Motohashi Japan	39	3.1k 1.2×	2.2k 1.1×	1.0k 1.0×	529 1.0×	304 0.8×	108	4.9k
Gang Zhou United States	34	2.9k 1.1×	2.1k 1.0×	1.1k 1.0×	297 0.6×	504 1.3×	71	4.6k
Alejandro López‐Soto Spain	32	2.3k 0.9×	1.6k 0.8×	1.3k 1.3×	650 1.3×	393 1.0×	63	4.4k
Ende Zhao United States	27	2.2k 0.9×	2.1k 1.0×	1.4k 1.4×	346 0.7×	645 1.6×	39	4.1k
Firouzeh Korangy United States	38	4.0k 1.5×	2.5k 1.2×	1.3k 1.2×	359 0.7×	420 1.1×	71	5.7k
Masahisa Jinushi Japan	35	3.9k 1.5×	2.1k 1.0×	1.4k 1.3×	292 0.6×	418 1.1×	72	5.6k
Tahseen H. Nasti United States	25	2.6k 1.0×	2.6k 1.3×	877 0.8×	420 0.8×	311 0.8×	58	4.4k
Atsushi Otsuka Japan	37	2.0k 0.8×	1.5k 0.7×	1.0k 1.0×	353 0.7×	212 0.5×	105	5.0k
Fanny Chalmin France	21	2.3k 0.9×	1.7k 0.8×	1.1k 1.1×	229 0.4×	269 0.7×	28	3.7k
Lynne Bingle United Kingdom	27	1.5k 0.6×	1.1k 0.6×	1.1k 1.1×	601 1.2×	549 1.4×	59	3.4k

Countries citing papers authored by Kenji Chamoto

Since Specialization

Citations

This map shows the geographic impact of Kenji Chamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Chamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Chamoto more than expected).

Fields of papers citing papers by Kenji Chamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Chamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Chamoto. The network helps show where Kenji Chamoto may publish in the future.

Co-authorship network of co-authors of Kenji Chamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Chamoto. A scholar is included among the top collaborators of Kenji Chamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Chamoto. Kenji Chamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Murakami, Kosaku, Tomonori Yaguchi, Kenji Chamoto, et al.. (2025). ICOS+CD4+ T cells define a high susceptibility to anti–PD-1 therapy–induced lung pathogenesis. JCI Insight. 10(10). 1 indexed citations

Sato, Shin‐ichi, et al.. (2024). Chemoproteomic Identification of Spermidine-Binding Proteins and Antitumor-Immunity Activators. Journal of the American Chemical Society. 146(24). 16412–16418. 7 indexed citations

Chamoto, Kenji, Baihao Zhang, Masaki Tajima, Tasuku Honjo, & Sidonia Fagarasan. (2023). Spermidine – an old molecule with a new age-defying immune function. Trends in Cell Biology. 34(5). 363–370. 34 indexed citations

Kurosaki, Takashi, Kenji Chamoto, Shinichiro Suzuki, et al.. (2023). The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Frontiers in Immunology. 14. 1325462–1325462. 12 indexed citations

Chamoto, Kenji, Tomonori Yaguchi, Masaki Tajima, & Tasuku Honjo. (2023). Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nature reviews. Immunology. 23(10). 682–695. 95 indexed citations breakdown →

Chamoto, Kenji, Ryusuke Hatae, & Tasuku Honjo. (2020). Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology. 25(5). 790–800. 117 indexed citations

Chowdhury, Partha S., Kenji Chamoto, Alok Kumar, & Tasuku Honjo. (2018). PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy. Cancer Immunology Research. 6(11). 1375–1387. 268 indexed citations breakdown →

Chamoto, Kenji, et al.. (2017). Role of PD-1 in Immunity and Diseases. Current topics in microbiology and immunology. 410. 75–97. 150 indexed citations

Ochi, Toshiki, Munehide Nakatsugawa, Kenji Chamoto, et al.. (2015). Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy. Cancer Immunology Research. 3(9). 1070–1081. 29 indexed citations

10.

Gibney, Barry C., Mi‐Ae Park, Kenji Chamoto, et al.. (2012). Detection of murine post-pneumonectomy lung regeneration by 18FDG PET imaging. EJNMMI Research. 2(1). 48–48. 12 indexed citations

11.

Chamoto, Kenji, Barry C. Gibney, Maximilian Ackermann, et al.. (2011). Alveolar macrophage dynamics in murine lung regeneration. Journal of Cellular Physiology. 227(9). 3208–3215. 40 indexed citations

12.

Takeshima, Tsuguhide, Kenji Chamoto, Daiko Wakita, et al.. (2010). Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: Its Potentiation by Combination with Th1 Cell Therapy. Cancer Research. 70(7). 2697–2706. 201 indexed citations

13.

Ashino, Shigeru, Daiko Wakita, Yoichiro Iwakura, et al.. (2010). A Th17-polarized cell population that has infiltrated the lung requires cells that convert to IFN-γ production in order to induce airway hyperresponsiveness. International Immunology. 22(6). 503–513. 18 indexed citations

14.

Wakita, Daiko, Kenji Chamoto, Takayuki Ohkuri, et al.. (2009). IFN-γ-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis. 30(8). 1408–1415. 31 indexed citations

15.

Murakawa, Masao, Megumi Goto, Yoshitaka Tanaka, et al.. (2009). ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-γ production by mouse activated T lymphocytes. Immunology Letters. 122(2). 193–197. 38 indexed citations

16.

Tajima, Masaki, Daiko Wakita, Daisuke Noguchi, et al.. (2008). IL-6–dependent spontaneous proliferation is required for the induction of colitogenic IL-17–producing CD8+ T cells. The Journal of Experimental Medicine. 205(5). 1019–1027. 146 indexed citations

17.

Yokouchi, Hiroshi, Koichi Yamazaki, Kenji Chamoto, et al.. (2007). A5-05: Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in powerful therapeutic antitumor immunity to murine lung cancer. Journal of Thoracic Oncology. 2(8). S324–S325. 3 indexed citations

18.

Togashi, Yuji, Kenji Chamoto, Daiko Wakita, et al.. (2007). Natural killer T cells from interleukin‐4‐deficient mice are defective in early interferon‐γ production in response to α‐galactosylceramide. Cancer Science. 98(5). 721–725. 4 indexed citations

19.

Ikeda, Hiroaki, Kenji Chamoto, Takemasa Tsuji, et al.. (2004). The critical role of type‐1 innate and acquired immunity in tumor immunotherapy. Cancer Science. 95(9). 697–703. 122 indexed citations

20.

Sato, Marimo, Kenji Chamoto, Takemasa Tsuji, et al.. (2001). Th1 Cytokine-Conditioned Bone Marrow-Derived Dendritic Cells Can Bypass the Requirement for Th Functions During the Generation of CD8+ CTL. The Journal of Immunology. 167(7). 3687–3691. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact